- Home
- ZENV vs INMB Comparison
ZENV vs INMB Comparison
Compare ZENV & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZENV | INMB |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9M | 49.2M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZENV | INMB |
|---|---|---|
| Price | $1.11 | $1.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.30 |
| AVG Volume (30 Days) | 25.8K | ★ 503.1K |
| Earning Date | 03-16-2026 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $201,426,369.00 | $50,000.00 |
| Revenue This Year | $12.75 | $173.21 |
| Revenue Next Year | N/A | $12,733.99 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.80 | 19.05 |
| 52 Week Low | $0.94 | $1.38 |
| 52 Week High | $3.03 | $11.64 |
Technical Indicators
Market Signals| Indicator | ZENV | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.59 | 44.73 |
| Support Level | $0.94 | $1.75 |
| Resistance Level | $1.15 | $1.90 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 42.42 | 5.74 |
Price Performance
Historical ComparisonAbout ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.